Literature DB >> 8170263

Hypercoagulability and thrombosis.

R L Bick1.   

Abstract

This article has stressed the common hereditary and acquired blood protein defects associated with thrombosis. The commonest hereditary defects appear to be antithrombin, protein C, and protein S deficiency, and the commonest acquired defects are anticardiolipin antibodies and the lupus anticoagulant. Therefore these are the defects that should first be looked for in an individual with unexplained thrombosis. If these commoner defects are not found, the rarer defects, including HC-II, plasminogen or t-PA deficiency, dysfibrinogenemia, or elevated PAI-1, should next be sought. The incidence of activated protein C cofactor deficiency is not yet clear but may also represent a common defect. Likewise, PAI-1 defects may, with time, be shown to be quite common. The importance of finding these defects has significant implications for therapy of the individual patient and for institution of family studies to identify, inform, and possibly treat others at risk. It is expected that as knowledge of hemostasis expands, more hereditary and acquired defects, such as elevated lipoprotein (a) or defects of extrinsic (tissue factor) pathway inhibitor may be associated with enhanced risks of thrombosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8170263     DOI: 10.1016/s0025-7125(16)30151-1

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  4 in total

Review 1.  Diagnosis and management of inherited and acquired thrombophilias.

Authors:  F A Spencer; R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Femoral artery embolus post-appendicectomy in a 12-year-old boy.

Authors:  G Henry; P Walker; I Kern
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

3.  Early graft thrombosis due to antithrombin III deficiency following CABG.

Authors:  P Kovacevic; L Velicki; N Komazec; B Vujin; V Ivanovic; M Golubovic
Journal:  Herz       Date:  2011-02-18       Impact factor: 1.443

4.  Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss.

Authors:  Nataliya Mar; Rebecca Kosowicz; Karen Hook
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.